FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Wednesday 09:00 PDT / 12:00 EDT / 16:00 GMT / 17:00 CET

Sponsor

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Ever-increasing demand for clinical and commercial-scale recombinant adeno-associated viral (rAAV) vector manufacturing has brought into sharp focus the need for new technological innovation to drive the requisite bioprocess productivity and efficiency gains.

In this webinar, Viralgen - a CDMO born as a joint venture between Askbio and Columbus Venture Partners, and recently acquired by Bayer - will discuss its approach to driving the industrialization of rAAV vector production, and present recent data obtained with the FectoVIR®-AAV transfection reagent for the production of rAAV in its Pro10™ cell line.

Attendees will learn:

How to optimize AAV productions based on improved transfection tools.
How to improve transfection reproducilbility and rAAv production at different production scales.

Mathieu Porte

Project Leader at Polyplus-transfection

Mathieu Porte is Bioproduction R&D Manager at Polyplus-transfection®. After obtaining his Biotechnology Engineering Degree from the renowned European School ESBS (Strasbourg, France), he worked as Research Assistant at New England Biolabs and UCSF. He joined Polyplus-transfection® in 2009. During 10 years in the Bioproduction R&D group, he carried out the development of several innovative transfection solutions dedicated to biomanufacturing.